share_log

CVS Health | 8-K: Current report

CVS Health | 8-K: Current report

西維斯健康 | 8-K:重大事件
美股SEC公告 ·  2024/11/06 19:37

Moomoo AI 已提取核心訊息

CVS Health reported Q3 2024 total revenues of $95.4 billion, up 6.3% YoY, while GAAP diluted EPS declined to $0.07 from $1.75. The quarter included charges to record premium deficiency reserves of approximately $1.1 billion ($0.63 per share) in the Health Care Benefits segment, primarily related to Medicare and individual exchange product lines.The Health Services segment saw adjusted operating income increase 17.4% to $2.2 billion, while Pharmacy & Consumer Wellness segment's adjusted operating income rose 14.9% to $1.6 billion. However, the Health Care Benefits segment recorded an adjusted operating loss of $924 million, compared to income of $1.5 billion in the prior year, driven by increased utilization and premium deficiency reserves.The company generated year-to-date operating cash flow of $7.2 billion and finalized an enterprise-wide restructuring plan, recording charges of approximately $1.2 billion, including store closures planned for 2025 and workforce optimization costs.
CVS Health reported Q3 2024 total revenues of $95.4 billion, up 6.3% YoY, while GAAP diluted EPS declined to $0.07 from $1.75. The quarter included charges to record premium deficiency reserves of approximately $1.1 billion ($0.63 per share) in the Health Care Benefits segment, primarily related to Medicare and individual exchange product lines.The Health Services segment saw adjusted operating income increase 17.4% to $2.2 billion, while Pharmacy & Consumer Wellness segment's adjusted operating income rose 14.9% to $1.6 billion. However, the Health Care Benefits segment recorded an adjusted operating loss of $924 million, compared to income of $1.5 billion in the prior year, driven by increased utilization and premium deficiency reserves.The company generated year-to-date operating cash flow of $7.2 billion and finalized an enterprise-wide restructuring plan, recording charges of approximately $1.2 billion, including store closures planned for 2025 and workforce optimization costs.
西維斯健康報告2024年第三季度總收入爲954億,較去年同期增長6.3%,而GAAP攤薄後每股收益下降至0.07美元,之前爲1.75美元。本季度包括約11億(每股0.63美元)的溢價不足準備金計入醫療保健福利部門,主要與醫療保險和個人交易所產品線相關。健康服務部門的調整後營業收入增長17.4%,達到22億,而藥房與消費健康部門的調整後營業收入增長14.9%,達到16億。然而,醫療保健福利部門錄得調整後營業虧損爲92400萬,而去年同期的收益爲15億,主要受利用率增加和溢價不足準備金驅動。該公司年初至今的經營現金流爲72億,並完成了一項企業範圍內的重組計劃,錄得約12億的費用,包括計劃於2025年關閉的門店和優化人力成本。
西維斯健康報告2024年第三季度總收入爲954億,較去年同期增長6.3%,而GAAP攤薄後每股收益下降至0.07美元,之前爲1.75美元。本季度包括約11億(每股0.63美元)的溢價不足準備金計入醫療保健福利部門,主要與醫療保險和個人交易所產品線相關。健康服務部門的調整後營業收入增長17.4%,達到22億,而藥房與消費健康部門的調整後營業收入增長14.9%,達到16億。然而,醫療保健福利部門錄得調整後營業虧損爲92400萬,而去年同期的收益爲15億,主要受利用率增加和溢價不足準備金驅動。該公司年初至今的經營現金流爲72億,並完成了一項企業範圍內的重組計劃,錄得約12億的費用,包括計劃於2025年關閉的門店和優化人力成本。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息